INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Loeillot Olivier sold RGEN

Director, Chief Executive Officer · REPLIGEN CORP · Common Stock

Side
SELL
Value
$1.60M
Shares
8,404
Price
$190
Executed
Sep 24, 2026
Disclosed
Sep 25, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 25, 2026 disclosed

RGEN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
18/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+14 / 25

    $1.6M reported value · 14.8% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RGEN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DR
    Douglass Brian RobbCHIEF PRODUCT OFFICER
    RGENREPLIGEN CORP
    Grant or award
    		A—
    675 sh
    		Oct 6, 2026Oct 8, 2026
    traded Oct 6, 2026
    		+2dSEC FORM 4

    Evidence

    13
    DR
    Douglass Brian RobbCHIEF PRODUCT OFFICER
    RGENREPLIGEN CORP
    Grant or award
    		A—
    700 sh
    		Oct 6, 2026Oct 8, 2026
    traded Oct 6, 2026
    		+2dSEC FORM 4

    Evidence

    12
    GK
    Garland Jason KCFO
    RGENREPLIGEN CORP
    Tax withholding
    		F$80K
    421 sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    9
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M$706K
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    15
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Open-market sale · 10b5-1 plan
    		SELL$863K
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    11
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M—
    4,542 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    11
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M—
    8,404 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    12
    LO
    Loeillot OlivierDirector, Chief Executive Officer
    RGENREPLIGEN CORP
    Option exercise · 10b5-1 plan
    		M$1.30M
    8,404 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-063572
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 24, 2026
    Published
    Sep 25, 2026
    Ingested by INSIDER
    Nov 5, 02:15 UTC
    Last re-read
    Nov 5, 02:15 UTC

    Extracted facts

    Filer
    Loeillot Olivier
    Role
    Director, Chief Executive Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    REPLIGEN CORP
    Ticker
    RGEN
    Shares
    8,404
    Price per share
    $190
    Value
    $1,596,760
    Execution date (reported)
    Sep 24, 2026
    Owned after transaction
    48.4K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 8,404
    • Price: $190

    = $1,596,760

    What this establishes

    Loeillot Olivier filed this Form 4 reporting a open-market sale of RGEN on Sep 24, 2026. It became public on Sep 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Loeillot Oliviercik:0001995525
    Issuer
    REPLIGEN CORPcik:0000730272

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.